BCRX · NASDAQ · STOCK
BioCryst Pharmaceuticals, Inc.
$10.35
52W $6.00 – $11.22
55/100
$2.63B
-7.2
0.55
Is BCRX Bullish or Bearish?
Mixed.
Innellis AI committee rates BioCryst Pharmaceuticals, Inc. (BCRX) Watch with a composite score of 55/100
, based on 6 analysts with 33% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +5.49 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -14.51 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 68.7% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 2.09) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 68.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 13.9x prices in significant intangible value — Value
- ROE of only -328.8% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.09 adds balance-sheet risk to the value case — Value
- RSI at 75 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
55/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 86%
of 192 Healthcare peers
Value Analyst
bearish
32
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 13.9x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 68.7% YoY -- genuine top-line momentum
Technical Analyst
neutral
51
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 75 is in overbought territory
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.09) amplifies downside in a stress scenario
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
52
/ 100 · Moderate confidence
News flow is mixed or quiet -- no strong signal either way right now
+ News sentiment is positive (+0.33 across 6 articles, 14d)
− Negative filing: Costs associated with exit or disposal (restructuring) (7d ago)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
75.0
Overbought
MACD Histogram
0.080
Bullish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Hh Hl
Support
$7.91
Resistance
$11.21
Bollinger %B
1.21
Above Upper Band
Price vs Moving Averages
EMA 9
$9.56
Above
EMA 21
$9.49
Above
EMA 50
$9.39
Above
EMA 200
$8.75
Above
Fundamental Analysis
Valuation
100
Profitability
27
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
-7.2×
P/B Ratio
-5.79×
PEG Ratio
0.00
Dividend Yield
0.00%
52W High
$11.22
52W Low
$6.00
Quality & Growth
ROE
-22144.7%
ROA
5131.9%
Gross Margin
2351.6%
Operating Margin
-3329.3%
Revenue Growth YoY
—
Debt / Equity
-0.90
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -7.2 (inexpensive relative to a 15-40x range); Price-to-book of -5.8x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -221.4%; Return on assets of 51.3%; Net margin of -40.9%; Gross margin of 23.5%; Current ratio of 2.32 (healthy short-term liquidity); Debt-to-equity of -0.90; Free cash flow per share is positive (1.41); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full BCRX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →